Up next

Autoplay

Breast cancer: Adjuvant exemestane combined with ovarian function suppression better than tamoxifen

0 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Visit http://www.ecancer.org for more.

Dr Pagani talks to ecancertv at ASCO 2014 about the results of a landmark study that was a joint analysis of two phase III trials, TEXT and SOFT, which demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when given with ovarian function suppression in premenopausal women with hormone-sensitive cancers.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Show more
0 Comments sort Sort By

Up next

Autoplay